Implantation of bitoric MICS IOL after CO-MICS to correct keratoconus

Article

Case study report

Materials and methods

OD: +2.00 -5.50 72 BCVA: 0.25

OS: +2.25 -3.25 138 BCVA: 0.33

After we had discussed different alternatives we decided to implant a bitoric customized toric IOL: AT. Torbi from Carl Zeiss Meditec (Jena, Germany). All the relevant data were entered into the CZM Online Calculator and a customized bitoric IOL was suggested.

The patient's eye reference axis and target axis were marked with a Tabo scheme CZM ocular with the Nd:YAG Laser. We prefer this method in comparison to any marker because it is much more convenient for the patient and can be less influenced by the patient, by rotating the eyeball or retracting the head. After we had done coaxial microincision phacoemulsification (COMICS, OS3 - Oertli Instrumente, Berneck, Switzerland) we implanted the bitoric IOL through a 1.6 mm incision with a wound assisted on axis technique under irrigation without the use of OVD. The orientation of the IOL was checked with a Breyer screen transparency (STACY).

Aberrometry and subjective refraction was tested 2 weeks postop: we achieved a perfect and acceptable result on the OD respective of OS.

Results

Conclusion

The implantation of customized bitoric MICS IOL through a 1.6 mm incision after CO-MICS seems to be a reliable tool to correct astigmatism in keratoconic cataract eyes.

Dr med. Detlev R.H. Breyer is a specialist in cataract and refractive surgery and is senior surgeon at the Breyer Eye Surgery, Dusseldorf, Germany. He may be reached by Email: d.breyer@breyer-augenchirurgie.de

Dr Breyer is a consultant to Oertli and Carl Zeiss Meditec.

References

1. J. Venter, J. Refract. Surg., 2009;25:759–764.

2. K.Kamiya, J. Refract. Surg., 2008;24:840–842.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.